研究開発費、繰延税金負債、資産の部 - 米国他2件
- 【期間】
| 年度 | 研究開発費 | 繰延税金負債 | 資産の部 - 米国 | 資産除去債務会計基準の適用に伴う影響額 | 株主資本合計 |
|---|
| 2007/03 | - | | - | | - | | - | | 2.76億 | |
| 2008/03 | 31百万 | | - | | - | | - | | 8.12億 | +194.7% |
| 2009/03 | - | | - | | - | | - | | 7.04億 | -13.3% |
| 2010/03 | - | | - | | - | | - | | 2.47億 | -65% |
| 2011/03 | - | | - | | - | | 1.1百万 | | 10.7億 | +331.9% |
| 2012/03 | - | | - | | - | | - | | 24.6億 | +130.6% |
| 2013/03 | 24百万 | -23.2% | - | | 13.6億 | | - | | 29.2億 | +18.8% |
| 2014/03 | 123百万 | +410.4% | - | | 11.7億 | -14.2% | - | | 31.4億 | +7.6% |
| 2015/03 | 89百万 | -27.2% | 6.2百万 | | 23.7億 | +102.9% | - | | 45.9億 | +46.1% |
| 2016/03 | 92百万 | +2.4% | 22百万 | +250.5% | 76.6億 | +223.5% | - | | 43.5億 | -5.1% |
| 2017/03 | 84百万 | -8.6% | - | | 86億 | +12.3% | - | | 48.5億 | +11.4% |
| 2018/03 | 119百万 | +42.4% | 4.9百万 | -77.4% | - | | - | | 40.7億 | -16% |
| 2019/03 | 62百万 | -47.7% | - | | - | | - | | 42.3億 | +3.8% |
| 2020/03 | 75百万 | +19.6% | - | | - | | - | | 31.7億 | -25% |
| 2021/03 | 154百万 | +106.6% | - | | - | | - | | 42.9億 | +35.4% |
| 2022/03 | 177百万 | +14.9% | - | | - | | - | | 56.7億 | +32.1% |
| 2023/03 | 206百万 | +16.2% | - | | - | | - | | 37億 | -34.6% |
| 2024/03 | - | | - | | - | | - | | 8.75億 | -76.4% |
